Jeune Aesthetics, a biotechnology company focused on aging skin, recently appointed of Marc Forth as CEO, effective Monday.
Forth has more than 30 years of commercial and executive leadership experience in therapeutics and aesthetics and has been a contributor on Jeune’s board of directors since 2021.
“I am thrilled to be joining Jeune as CEO as it takes the next step forward in its growth journey,” Forth said. “With Krystal’s FDA (Food and Drug Administration)-validated gene delivery platform at its core, Jeune is uniquely positioned to meet the growing demand for fundamentally rejuvenative treatments to address aging skin. I look forward to working alongside the talented team to create long-term value, drive investment, and establish Jeune as the leader in rejuvenative aesthetics.”
Jeune Aesthetics is a wholly-owned subsidiary of Pittsburgh-based Krystal Biotech, a commercial-stage biotechnology company focused on genetic medicines.
Forth previously was AEON Biopharma president and CEO. He led the exclusive regional licensure for therapeutic use of botulinum toxin type A complex agent ABP-450 as well as oversaw ABP-450’s clinical development program.
Prior to AEON Biopharma, Forth served for 16 years at Allergan PLC where he was senior vice president and U.S. Neurosciences, Urology and Medical Dermatology Divisions division head.